What a new frontier in mental health means for Maryland

PUBLISHED: April 21, 2026 | www.baltimoresun.com

In a move that has drawn both hope and skepticism, President Donald Trump signed an executive order to fast-track research and access to psychedelic-assisted treatments, particularly for veterans suffering from PTSD and trauma. For many, the reaction has been simple: It’s about time. But the significance of this moment runs deeper than politics. It signals a potential shift in how America approaches mental health, one that carries both promise and responsibility, especially for communities here in Maryland.

For decades, the mental health system has relied on a familiar set of tools: antidepressants, anti-anxiety medications and traditional talk therapy. These treatments have helped millions, but they have also left many behind. Nowhere is that gap more visible than among veterans and individuals struggling with severe, treatment-resistant depression and addiction.

In Maryland, this challenge is not abstract; it is local and immediate. Baltimore, a city of resilience and complexity, continues to confront high rates of trauma, addiction and mental health strain. Veterans returning to communities across the state, from Baltimore City to Prince George’s County to the Eastern Shore, often carry invisible wounds that traditional care has not fully addressed. At the same time, the opioid crisis continues to take a devastating toll, with thousands of Maryland families impacted each year.

This executive order is, at its core, an acknowledgment that the current system is not reaching everyone.

By accelerating federal support for clinical trials and creating pathways for controlled access, the policy reframes substances once dismissed outright as potential tools for healing. Compounds such as psilocybin and MDMA, long associated with counterculture, are now being studied in leading research institutions. Maryland itself is home to some of the most respected centers of medical research in the world, including Johns Hopkins University, which has been at the forefront of studying psychedelic therapies for depression, addiction and end-of-life anxiety.

Early findings suggest that, under strict clinical supervision, these therapies may help patients process trauma in ways that traditional treatments have not achieved. Some studies indicate that a limited number of guided sessions can produce meaningful, lasting improvements, an outcome that would represent a significant departure from the long-term, daily medication model that dominates current care.

For Maryland, the implications are profound. If validated and responsibly implemented, these treatments could offer new pathways for veterans, first responders and individuals battling addiction groups that are deeply embedded in the fabric of Baltimore and the broader state.

But discipline matters.

The science, while promising, is still developing. Many studies remain limited in scale, and long-term outcomes are not fully understood. Certain substances being explored carry real risks if not administered in controlled settings. The enthusiasm surrounding these therapies must not outpace the evidence required to support them. In medicine, hope is not enough; data must lead.

This moment also reflects a broader philosophical shift. Historically, mental health treatment has focused on managing symptoms over time, stabilizing patients through ongoing medication and therapy. Psychedelic-assisted treatments suggest a different model: targeted, short-duration interventions aimed at addressing the root of trauma. If proven effective, this approach could reshape not only how treatment is delivered, but how recovery is defined.

Yet with that possibility comes a series of serious questions. How will these therapies be regulated at the state level? How will Maryland ensure that access is equitable, not limited to those with financial means? How do we protect patients while allowing innovation to move forward? And how do we prevent the commercialization of these treatments from outpacing their medical validation?

These are not theoretical concerns. They will determine whether this moment becomes a true breakthrough or another cycle of overpromise followed by disappointment.

There is also a moral dimension that cannot be ignored. Veterans in Maryland, along with countless families affected by addiction and trauma, deserve solutions that go beyond incremental change. If there are treatments that may ease that burden, there is an obligation to explore them. But that obligation must be matched with caution. The goal is healing, not experimentation without guardrails.

The balance is clear: urgency without recklessness, innovation without abandoning standards.

This executive order does not resolve the challenges facing mental health care in Maryland or across the nation. But it does open a door, one that has been closed for generations. It acknowledges that the current system has limits and that new approaches must be explored with seriousness and discipline.

For Baltimore, for Maryland and for the country, the question is not whether change is coming. It is whether we are prepared to guide that change responsibly.

The promise is real. The risks are real. And the responsibility now is to ensure that this moment is driven not by hype or hesitation, but by evidence, integrity and a commitment to those who need it most.

Armstrong Williams (www.armstrongwilliams.com; @arightside) is a political analyst, syndicated columnist and owner of the broadcasting company, Howard Stirk Holdings. He is also part owner of The Baltimore Sun.

©️ 2026 Baltimore Sun